Xeris Pharmaceuticals, Inc., a pharma company with novel formulation technology platforms for ready-to-use injectable drug formulations, entered an agreement to acquire Strongbridge Biopharma, a global commercial-stage biopharma company focused on therapies for rare diseases, for stock and contingent value rights valued at approximately $267 million.   The transaction, which has been unanimously approved by the boards of both companies, is expected to close 4Q21, subject to customary closing c...